Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Alzamend Neuro, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 26 | 24 | −2 |
| Shares | 6.22M | 6.15M | −77.8K (−1.3%) |
| Value | $2.64M | $3.13M | +$489.6K (+18.5%) |
New holders (2)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Integrated Investment Consultants, LLC | 40,000 | $20.4K | 0.01% |
| Simplex Trading, LLC | 479 | $0 | 0.00% |
Sold out (4)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 36,281 | $15.4K |
| Jane Street Group, LLC | 12,009 | $5.10K |
| Centaurus Financial, Inc. | 12,000 | $5.00K |
| Bank of America Corp | 264 | $112 |